Infant Bacterial Therapeutics AB Class B

INFANT BACTERIAL THERAPEUTICS AB's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, INFANT BACTERIAL THERAPEUTICS AB has 13.47M shares outstanding.

As of June 30, 2026, INFANT BACTERIAL THERAPEUTICS AB maintains a current ratio of 1.67, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, INFANT BACTERIAL THERAPEUTICS AB posted a negative return on equity (ROE) of -87.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.27, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

As of the close on July 7, 2026, INFANT BACTERIAL THERAPEUTICS AB's stock has declined approximately 16.46% over the past 52 weeks.

Over the twelve months ended June 30, 2026, INFANT BACTERIAL THERAPEUTICS AB generated - - in revenue and converted that into -8.45M in net income, yielding earnings per share of -0.63. EBITDA reached -8.68M, while operating income came in at -8.77M.

These figures are as of June 30, 2026. Total book value stands at 5.47M, with working capital of 4.67M providing operational flexibility.

INFANT BACTERIAL THERAPEUTICS AB produced -6.61M in operating cash flow over the twelve months ended June 30, 2026.

INFANT BACTERIAL THERAPEUTICS AB's most recent stock split took place on January 11, 2018.